ClinicalTrials.gg
Not yet recruitingNCT06897527Updated Jul 8, 2025

A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)

A Phase 4 interventional study of Dostarlimab in Neoplasms, Endometrial, sponsored by GlaxoSmithKline. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-08.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing dostarlimab in Endometrial Neoplasms — 12 open to participants now, 17 under way, 3 of them phase 3. dostarlimab · Endometrial Neoplasms.

Planned enrollment
6th of 18
100 · median 46
Started
2025
with 3 others
Phase 4
2 of 18
2 open now
Primary completion
2027-01
later than 6 of 16 live
Registered
12th of 18
by date
Lead sponsor
5 of 18
GlaxoSmithKline

Among the 18 studies testing dostarlimab in Endometrial Neoplasms, this one is the 6th largest by planned enrollment, is one of 4 that started in 2025, is one of 2 in phase 4, reaches primary completion later than 6 of the 16 other live ones, and was the 12th registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

12 of the 18 studies testing dostarlimab in Endometrial Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About dostarlimab

dostarlimab: first FDA approval 2021 (JEMPERLI), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing dostarlimab in Endometrial Neoplasms, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the safety profile of dostarlimab in Indian adults with recurrent or advanced endometrial cancer.

03

Conditions studied

  • Neoplasms, Endometrial

Keywords

  • Dostarlimab
  • Endometrial cancer
  • dMMR
  • MSI-H
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants ≥18 years of age, at the time of signing the .
  • Documented case of dMMR/MSI-H recurrent or advanced EC that has progressed on or following prior treatment with platinum containing regimen.
  • Eligible for dostarlimab treatment according to the approved prescribing information and the investigator's clinical judgement.
  • (Women of childbearing potential) agree to use from screening through at least 120 days after the last dose.
  • Negative serum or urine pregnancy test at most 72 hours prior to the first dose of study medication.
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol, in accordance with applicable laws.

Exclusion criteria

Exclusion Criteria:

  • Known active hepatic disease, End-Stage Renal Disease (ESRD) or known case of serious, uncontrolled medical disorder/active infections which precludes participant's inclusion in the study as per the investigator's judgement.
  • Either the history of to of the study drug or to drugs with a similar chemical structure or class of the study drug.
  • Received prior therapy with an anti- programmed death receptor 1 (), anti-PD-1- ligand-1 (anti-PD-L1) agent.
  • Has a diagnosis of immunodeficiency or is receiving systemic therapy or any other form of therapy within 7 days prior to the first dose of study treatment.
  • Received a within 14 days of planned start of study therapy.
  • Participation in another clinical study with a study drug administered in the last 3 months.
  • Pregnant, breastfeeding, or expecting to conceive while receiving study treatment and for up to 120 days after the last dose of study treatment.
  • Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Dostarlimab

    Drug: Dostarlimab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Grade 3 or greater Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to 25 weeks

Secondary outcomes

  1. Number of Participants with any TEAEs

    Time frame: Up to 25 weeks

  2. Number of Participants with Serious Adverse Events (SAEs), treatment related Adverse Events (AEs), treatment related SAEs, treatment related fatal AEs, non-fatal SAEs

    Time frame: Up to 25 weeks

  3. Number of Participants with AEs leading to discontinuation of treatment, AEs leading to death, AEs leading to study withdrawal and AEs leading to dose modification

    Time frame: Up to 25 weeks

  4. Change from baseline in hematology parameters: neutrophils, lymphocytes, monocytes, eosinophils, basophils and platelet count (Giga cells per Liter)

    Time frame: Baseline (Day 1) up to 25 weeks

  5. Change from baseline in hematology parameter: Red Blood Cell (RBC) count (Trillion cells per Liter)

    Time frame: Baseline (Day 1) up to 25 weeks

  6. Change from baseline in hematology parameter: Hemoglobin (Hb) (Grams per Liter)

    Time frame: Baseline (Day 1) up to 25 weeks

  7. Change from baseline in hematology parameter: Reticulocytes (Percentage of reticulocytes)

    Time frame: Baseline (Day 1) up to 25 weeks

  8. Change from baseline in hematology parameter: Mean Corpuscular Volume (MCV) (Femtoliters)

    Time frame: Baseline (Day 1) up to 25 weeks

  9. Change from baseline in hematology parameter: Mean Corpuscular Hemoglobin (MCH) (Picograms)

    Time frame: Baseline (Day 1) up to 25 weeks

  10. Change from baseline in clinical chemistry parameters: Blood urea nitrogen [BUN], glucose, calcium, sodium, and potassium levels (Millimoles per Liter)

    Time frame: Baseline (Day 1) up to 25 weeks

  11. Change from baseline in clinical chemistry parameters: Total bilirubin, direct bilirubin and creatinine levels (Micromoles per Liter)

    Time frame: Baseline (Day 1) up to 25 weeks

  12. Change from baseline in clinical chemistry parameters: Total protein levels (Gram per liter)

    Time frame: Baseline (Day 1) up to 25 weeks

  13. Change from baseline in clinical chemistry parameters: Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) levels (International units per liter)

    Time frame: Baseline (Day 1) up to 25 weeks

  14. Change from Baseline in Vital signs: systolic blood pressure (SBP) and diastolic blood pressure (DBP) (Millimeters of mercury [mmHg])

    Time frame: Baseline (Day 1) up to 25 weeks

  15. Change from Baseline in Vital signs: pulse rate (Beats per minute)

    Time frame: Baseline (Day 1) up to 25 weeks

  16. Change from Baseline in Vital signs: body temperature (Degrees Celsius)

    Time frame: Baseline (Day 1) up to 25 weeks

  17. Change from Baseline in Vital signs: respiratory rate (breaths per minute)

    Time frame: Baseline (Day 1) up to 25 weeks

  18. Change from Baseline in electrocardiogram (ECG) values: Heart rate (Beats per minute)

    Time frame: Baseline (Day 1) up to 25 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2025; primary completion for Jan 2027, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2025
First posted
Mar 27, 2025
StartEst.
Jul 15, 2025
Primary completionEst.
Jan 13, 2027
CompletionEst.
Jan 13, 2027
Last update
Jul 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06897527
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 27, 2025
Start date
Jul 15, 2025 (estimated)
Primary completion
Jan 13, 2027 (estimated)
Completion
Jan 13, 2027 (estimated)
Last update
Jul 8, 2025

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dostarlimab

Start the discussion